New drug cocktail aims to slow kidney disease in IgA patients
NCT ID NCT07030894
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether combining budesonide (Nefecon) and ambrisentan can reduce protein in the urine and preserve kidney function in people with IgA nephropathy who are at risk of kidney failure. About 129 adults will take both pills daily for 36 weeks. Researchers will measure changes in urine protein, kidney filtration rate, and immune markers to see if the combination is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- budesonide (Nefecon) and ambrisentan
- What this could lead to
- If successful, this combination could offer a new way to slow kidney damage and delay the need for dialysis or transplant in people with IgA nephropathy.
- What could go wrong
- This is a single-arm, early-phase trial with no placebo group, so results may be less reliable. Side effects from the drugs are possible, and the benefit may not be confirmed in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Mapping the Real-World treatment landscape for IgA nephropathy
- Could a phone app be the key to managing kidney disease?
- A simple test could forecast kidney disease progression